Account wins

MedThink Communications has been retained by Salix Pharmaceuticals to launch and promote its newest product under development, an orally disintegrating form of metoclopramide. Salix recently licensed the rights to market the orally disintegrating metoclopramide tablet and will bring the drug to market following approval from the FDA. MedThink is also agency of record for several of Salix's gastrointestinal products, including the colonoscopy preparation OsmoPrep (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) and the targeted antibiotic Xifaxan (rifaximin).
You must be a registered member of MMM to post a comment.

Next Article in Channel